Recharging life. By restoring cellular energy

Cellergy is pioneering the large-scale production of intact, functional mitochondria in its mission to transform human health.

Discover Cellergy Investor enquiries

01The company

Revolutionizing regenerative medicine

Cellergy is producing mitochondria in large quantity from human primary sources: fully matched, allogeneic and purified, delivered by IV for systemic, repeated administration in major indications such as CNS disorders, muscle degeneration and aging.

01
Human primary source
Non-transformed primary cells with excellent respiration capacity.
02
Fully matched, allogeneic
Young, healthy donor mitochondria, matched to each recipient.
03
Systemic and repeatable
Given by intravenous infusion, so it can reach the whole body, and be given again.

02Why mitochondria

The cell’s powerhouse

Mitochondria turn the fuel from food into ATP, the energy that protein synthesis, DNA repair, muscle contraction and waste removal all run on. It is critical to every function of the cell.

An electron micrograph of a single cell containing dozens of mitochondria, each lined with folded inner membranes, glowing magenta on black — Fig. 02One cell, packed with mitochondria. The fine folds inside each one, the cristae, are where ATP is made. Transmission electron micrograph, inverted.

500–2,500: mitochondria in a single human cell, depending on the cell type
13: proteins of the respiratory machinery, encoded by the mitochondrion’s own small, circular DNA
~1,200: further mitochondrial proteins, encoded in the cell nucleus

Most abundant where energy demand is highest

Muscle
Brain
Liver

03The problem

When energy fails

Degenerative diseases, and aging, often start with damage to mitochondria.

01
Mutations accumulate.
Errors build up in mitochondrial DNA, in the very genes that code for the machinery making the cell’s energy.
02
Membranes oxidize.
The membrane lipids get oxidized, damaging the folded inner membrane where ATP is made.
03
Energy runs out.
Once energy production is depleted, the cell starts to degenerate. Across a tissue, that is disease. Across a body, it is aging.
04
Recharge.
Cellergy’s answer is to replace the power supply itself: young, healthy mitochondria, delivered by IV, to energize cells again.

04The platform

Source is everything

Mitochondria source is the key to making an effective therapy. Cellergy’s is proprietary, and so is the process that turns it into medicine.

A single primary human fibroblast, its thread-like mitochondria glowing magenta across a teal cytoskeleton — A primary human cell: its mitochondria (magenta) threaded along the cytoskeleton (teal). Confocal micrograph.

01Proprietary source

Primary. High-quality. Scalable.

Primary: Non-transformed primary cells.
High-quality: Excellent respiration capacity.
Scalable: Massive expansion of the source cells, in a cost-efficient process.

02Manufacturing

GMP-grade, at scale.

A large-scale mitochondria manufacturing process, GMP-grade, built to enable systemic, repeated administration across multiple indications.

Clinical-grade production with Made Scientific, a US cGMP cell-therapy manufacturer.

03Allogeneic matching

Donors

Recipient

Matched by machine learning.

Transplanting mitochondria from a young, healthy donor into an aging or degenerative recipient requires careful matching. Our machine-learning model predicts donor–recipient matching, to make allogeneic mitochondrial transplantation safe and effective.

From donor to patient

01
Source.
Primary, non-transformed cells from young, healthy donors.
02
Expand.
Source cells expanded massively, in a cost-efficient process.
03
Purify.
Intact, functional mitochondria isolated to GMP grade.
04
Match.
The machine-learning model pairs donor and recipient.
05
Infuse.
Delivered intravenously, systemically and repeatably.

The result

Young, healthy mitochondria, energizing the recipient’s cells.

Fluorescence micrograph of human stem cells extending magenta, mitochondria-filled strands towards neighbouring teal immune cells — Fig. 03Cells trade mitochondria naturally. Here, human stem cells (mitochondria in magenta) pass them to immune cells (teal). Confocal micrograph.

05Indications

One therapy. Many diseases

Mitochondria purified from healthy donors, developed to restore cellular energy production in conditions driven by mitochondrial dysfunction, including metabolic disorders, neurodegenerative diseases and age-related conditions.

Mitochondrial disease (Mitochondrial)
Alzheimer’s (Neurodegenerative)
Parkinson’s (Neurodegenerative)
ALS (Neurodegenerative)
Huntington’s (Neurodegenerative)
Multiple sclerosis (Neurodegenerative)
Epilepsy (Neurological)
Cerebral palsy (Neurological)
Autism (Neurological)
Muscular dystrophy (Muscle & fatigue)
Fibromyalgia (Muscle & fatigue)
Chronic fatigue (Muscle & fatigue)
Cardiomyopathy (Cardiometabolic)
Diabetes (Cardiometabolic)
Obesity (Cardiometabolic)
Cancer (Oncology & aging)
Aging (Oncology & aging)

Potential indications. CLG-001 is investigational and has not been approved for any use.

06Our vision

Transforming human health

By providing the power of young and healthy mitochondria to energize cells, fight degenerative diseases and enhance healthy longevity.

07Leadership

Our Leadership

Founders and operators with decades in biotech, from company creation and clinical pipelines to cell-therapy commercialization.

Rachel DiamantMSc Eng.
Co-founder & Chief Executive Officer
- 20 years as an entrepreneur in biotech.
- Co-founder of Emendo Biotherapeutics, where she served as CBO and led IP and clinical pipeline development.
- BSc in Biotechnology Engineering from the Technion; MSc from the Weizmann Institute.
Robert E. MargolinMSc, MBA
Chief Business Officer
- 20 years in biotechnology, with a focus on cell and gene therapy.
- Former VP of Commercial at Akron Biotech, with leadership roles at TrakCel and Cognate BioServices.
- Deep expertise in business development, commercial strategy and advanced therapeutics.
Ganit YardenPhD
Chief Technology Officer
- Accomplished biotech executive.
- Leadership roles at Teva, Merck and Compugen.
- PhD in Biochemistry from the Weizmann Institute.

08Board

Our board

Company builders who have taken biotechs from founding to approval, and to exit.

$300M: Sale of Emendo Biotherapeutics, led by David Baram as CEO
$500M+: Raised across David Baram’s career
6: FDA approvals from companies Peter Kash co-founded or financed
$23B+: Peak aggregate market value of those companies

Peter KashEdD, MBA
Chairman of the Board
- Biotech entrepreneur, investor and educator for more than 35 years.
- Co-founder or banker of PolaRx, Keryx Biopharmaceuticals, Kite Pharma, Intercept Pharmaceuticals, ID Biomedical, TargImmune Therapeutics, iOncologi and others.
- Led to 6 FDA approvals and more than $23 billion in peak aggregate market value.
David BaramPhD
Co-founder, Board member
- 25 years as an entrepreneur and a leading CEO.
- Co-founded Emendo Biotherapeutics and, as CEO, led it to a $300M sale.
- More than $500M raised over his career.
- PhD from the Weizmann Institute under Nobel laureate Ada Yonath.
Rachel DiamantMSc Eng.
Chief Executive Officer, Board member
- 20 years as an entrepreneur in biotech; co-founder of Emendo Biotherapeutics.
Todd WiderMD
Board member
- Surgeon, Columbia University.
- Served as CMO and Executive Chairman of Emendo Biotherapeutics.
- Extensive experience as a director of global biotech companies, and as an advisor to large biotech investors.
Andrew Haimovici
Board member
- Investor at TABLE Management LP, Bill Ackman’s investment vehicle.
- Experience investing across private and public companies.
- Director of Bremont Watch Company, with a strong perspective on investment strategy, growth and value creation.